EUVIMEDEUVIMED entdecken
Crossref

An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus

Juan Tao, Xinrui Lu, Yuning Wei, Jiayi Feng, Jinlong Yang iD, Jianping Qi iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.5c24385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Juan Tao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced Drug Formulations f…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Ionic Liquids, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Huai'an Science and Technology Bureau, Lingang Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral delivery of peptide therapeutics remains challenging due to gastrointestinal degradation, poor epithelial permeability, and extremely low bioavailability. To address these limitations, we developed an enteric solid formulation based on sorbic acid-choline ionic liquids (ILs) for the oral delivery of semaglutide (Sema), a glucagon-like peptide-1 (GLP-1) analogue. The IL-based enteric system was designed to enhance peptide stability, reduce gastric degradation, and promote intestinal absorption. In vitro studies demonstrated strong resistance to acidic conditions and pH-responsive release in simulated intestinal fluid. In vivo imaging further revealed prolonged intestinal retention of the IL-loaded enteric particles. Pharmacokinetic evaluation showed a 2.3-fold increase in maximum plasma concentration compared to the reference Rybelsus. In type 2 diabetes mellitus (T2DM) mice, the formulation achieved glucose-lowering efficacy comparable to subcutaneous Sema administration, with additional improvements in hepatic histology. Importantly, repeated-dose studies indicated favorable systemic and gastrointestinal tolerability under the tested conditions. Collectively, these results demonstrate that IL-based enteric formulation enhances oral peptide exposure while maintaining safety, offering a promising strategy for noninvasive T2DM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesDiabetes Mellitus, Type 2Ionic LiquidsHypoglycemic AgentsDiabetes Mellitus, ExperimentalSemaglutideAnimalsAdministration, OralMiceMaleHumans

Stichwörter der Autor:innen

bioavailabilityionic liquidoral peptide deliverysemaglutidetype 2 diabetes mellitus

Substanzen

SemaglutideGlucagon-Like PeptidesIonic LiquidsHypoglycemic Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai 201203, Ch…
  • School of Chinese Medicine, Jiangsu College of Nursing, Huaian 223001, China.
  • Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China.

ORCID-Profile: Jinlong Yang, Jianping Qi

Förderung

  • Huai'an Science and Technology Bureau
  • Lingang Laboratory

Zitieren

APA

Tao, J., Lu, X., Wei, Y., Feng, J., Yang, J., & Qi, J. (2026). An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c24385

Vancouver

Tao J, Lu X, Wei Y, Feng J, Yang J, Qi J. An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c24385

BibTeX
@article{Tao2026,
  author = {Tao, Juan and Lu, Xinrui and Wei, Yuning and Feng, Jiayi and Yang, Jinlong and Qi, Jianping},
  title = {An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.5c24385}
}
Kostenlos starten →